ESPR

MKT CAP:$391M

Esperion Therapeutics, Inc.

Market Cap

$391M

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Healthcare·Drug·🇺🇸·NASDAQ

Stock Price

$1.91-$1.80 (-48.52%)

Apr 23, 2026

Company Details

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXL...

CEO

Sheldon L. Koenig

IPO Date

Jun 26, 2013

Website

www.esperion.com

Key Metrics TTM

Revenue

$403M

+21.3% YoY

Net Income

-$23M

EPS (Diluted)

-$0.17

Free Cash Flow

-$13M

Revenue / Share

$1.42

Gross Margin

64.4%

Operating Margin

15.0%

Net Margin

-5.6%

FCF Margin

-3.2%

P/S

1.0x

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Mar 10, 2026

$403M+21.3%EPS -$0.11

Q4 2025

Mar 10, 2026

$168M+143.7%EPS $0.22

Q3 2025

Nov 6, 2025

$87M+69.1%EPS -$0.16

Q2 2025

Aug 13, 2025

$82M+11.6%EPS -$0.02

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$19M	$12M	-$43M
Q2 22	$19M	$10M	-$52M
Q3 22	$19M	$12M	-$42M
Q4 22	$19M	$15M	-$43M
Q1 23	$24M	$13M	-$49M
Q2 23	$26M	$19M	-$37M
Q3 23	$34M	$21M	-$28M
Q4 23	$32M	$21M	-$42M
Q1 24	$138M	$128M	$72M
Q2 24	$74M	$58M	$3M
Q3 24	$52M	$34M	-$16M
Q4 24	$69M	$43M	-$4M
Q1 25	$65M	$33M	-$22M
Q2 25	$82M	$54M	$7M
Q3 25	$87M	$32M	-$10M
Q4 25	$168M	$141M	$85M

Valuation

Quarter	P/S	P/E
Q1 22	4.4x	—
Q2 22	5.8x	—
Q3 22	5.4x	—
Q4 22	5.2x	—
Q1 23	4.8x	—
Q2 23	4.4x	—
Q3 23	3.8x	—
Q4 23	3.4x	—
Q1 24	1.7x	—
Q2 24	1.4x	—
Q3 24	1.3x	—
Q4 24	1.2x	—
Q1 25	1.5x	—
Q2 25	1.5x	—
Q3 25	1.3x	—
Q4 25	1.0x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$39M	-$39M
Q2 22	-$51M	-$51M
Q3 22	-$43M	-$43M
Q4 22	-$42M	-$42M
Q1 23	-$54M	-$54M
Q2 23	-$25M	-$25M
Q3 23	-$19M	-$19M
Q4 23	-$37M	-$37M
Q1 24	$54M	$54M
Q2 24	-$7M	-$7M
Q3 24	-$35M	-$35M
Q4 24	-$35M	-$35M
Q1 25	-$23M	-$23M
Q2 25	-$31M	-$31M
Q3 25	-$4M	-$4M
Q4 25	$45M	$45M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$73.0K
Q2 24	$77.0K
Q3 24	$167.0K
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$189.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+136.1%	-31.9%
Q2 22	-53.7%	-2.7%
Q3 22	+31.7%	-13.6%
Q4 22	+22.2%	-13.7%
Q1 23	+29.2%	+18.0%
Q2 23	+36.9%	-11.8%
Q3 23	+79.0%	+1.5%
Q4 23	+71.4%	+21.7%
Q1 24	+466.1%	-10.2%
Q2 24	+186.3%	+13.4%
Q3 24	+52.0%	+10.0%
Q4 24	+114.3%	-1.5%
Q1 25	-52.8%	+33.0%
Q2 25	+11.6%	+5.7%
Q3 25	+69.1%	+43.8%
Q4 25	+143.7%	+13.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$4M	23.6%
Q2 22	$4M	18.7%
Q3 22	$0	0.0%
Q4 22	$0	0.0%
Q1 23	$3M	11.9%
Q2 23	$3M	12.3%
Q3 23	$3M	8.8%
Q4 23	$3M	9.1%
Q1 24	$3M	2.3%
Q2 24	$3M	4.0%
Q3 24	$3M	5.9%
Q4 24	$3M	4.1%
Q1 25	$2M	3.8%
Q2 25	$3M	3.2%
Q3 25	$2M	2.7%
Q4 25	$2M	1.4%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$24M	—	—	$30M
Q2 22	$32M	—	—	$30M
Q3 22	$29M	—	—	$25M
Q4 22	$33M	—	—	$24M
Q1 23	$31M	—	—	$30M
Q2 23	$22M	—	—	$34M
Q3 23	$15M	—	—	$33M
Q4 23	$18M	—	—	$45M
Q1 24	$13M	—	—	$42M
Q2 24	$11M	—	—	$44M
Q3 24	$10M	—	—	$40M
Q4 24	$11M	$11M	$26M	—
Q1 25	$13M	—	—	$43M
Q2 25	$7M	—	—	$40M
Q3 25	$14M	—	—	$42M
Q4 25	$14M	—	—	$41M

Revenue Segments

Quarter	Collaboration Revenue	Product
Q4 22	$4M	$15M
Q1 23	$7M	$17M
Q2 23	$5M	$20M
Q3 23	$14M	$20M
Q4 23	$11M	$21M
Q1 24	$113M	$25M
Q2 24	$46M	$28M
Q3 24	$21M	$31M
Q1 25	$30M	$35M
Q2 25	$42M	$40M
Q3 25	$47M	$41M
Q4 25	$125M	$44M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$150M	$68M	$219M
Q2 22	$123M	$63M	$186M
Q3 22	$159M	$30M	$189M
Q4 22	$125M	$42M	$167M
Q1 23	$145M	$17M	$162M
Q2 23	$138M	$0	$138M
Q3 23	$115M	$0	$115M
Q4 23	$82M	$0	$82M
Q1 24	$227M	$0	$227M
Q2 24	$189M	$0	$189M
Q3 24	$145M	$0	$145M
Q4 24	$145M	$0	$145M
Q1 25	$115M	$0	$115M
Q2 25	$86M	$0	$86M
Q3 25	$92M	$0	$92M
Q4 25	$168M	$0	$168M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	61M	+65.4%	+134.5%
Q2 22	63M	+3.7%	+141.1%
Q3 22	68M	+7.2%	+156.3%
Q4 22	73M	+8.4%	+99.4%
Q1 23	78M	+6.7%	+28.7%
Q2 23	109M	+39.3%	+72.8%
Q3 23	112M	+2.4%	+65.0%
Q4 23	112M	+0.5%	+53.0%
Q1 24	190M	+68.7%	+141.8%
Q2 24	189M	-0.4%	+72.8%
Q3 24	195M	+3.3%	+74.2%
Q4 24	196M	+0.3%	+74.0%
Q1 25	196M	+0.3%	+3.4%
Q2 25	197M	+0.4%	+4.3%
Q3 25	198M	+0.7%	+1.7%
Q4 25	285M	+43.6%	+45.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$86.4K	218
Q2 22	$86.4K	218
Q3 22	$87.1K	218
Q4 22	$94.6K	199
Q1 23	$122.3K	199
Q2 23	$129.6K	199
Q3 23	$170.7K	199
Q4 23	$134.4K	240
Q1 24	$573.9K	240
Q2 24	$307.6K	240
Q3 24	$215.1K	240
Q4 24	$227.3K	304
Q1 25	$213.8K	304
Q2 25	$271.0K	304
Q3 25	$287.2K	304
Q4 25	$11.2K	15K

Revenue / Employee